|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
1994-12-23
|
|
pubmed:abstractText |
Mouse mammary tumor virus (MMTV) encodes a superantigen (SAg) that promotes stable infection and virus transmission. Upon subcutaneous MMTV injection, infected B cells present SAg to SAg-reactive T cells leading to a strong local immune response in the draining lymph node (LN) that peaks after 6 d. We have used the reverse transcriptase inhibitor 3'-azido-3'-deoxythymidine (AZT) to dissect in more detail the mechanism of SAg-dependent enhancement of MMTV infection in this system. Our data show that no detectable B or T cell response to SAg occurs in AZT pretreated mice. However, if AZT treatment is delayed 1-2 d after MMTV injection, a normal SAg-dependent local immune response is observed on day 6. Quantitation of viral DNA in draining LN of these infected mice indicates that a 4,000-fold increase in the absolute numbers of infected cells occurs between days 2 and 6 despite the presence of AZT. Furthermore MMTV DNA was found preferentially in surface IgG+ B cells of infected mice and was not detectable in SAg-reactive T cells. Collectively our data suggest that MMTV infection occurs preferentially in B cells without SAg involvement and is completed 1-2 d after virus challenge. Subsequent amplification of MMTV infection between days 2 and 6 requires SAg expression and occurs in the absence of any further requirement for reverse transcription. We therefore conclude that clonal expansion of infected B cells via cognate interaction with SAg-reactive T cells is the predominant mechanism for increasing the level of MMTV infection. Since infected B cells display a memory (surface IgG+) phenotype, both clonal expansion and possibly longevity of the virus carrier cells may contribute to stable MMTV infection.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/7525852-1310360,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7525852-1316806,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7525852-1316932,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7525852-1706480,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7525852-1748148,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7525852-1848685,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7525852-185796,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7525852-1903543,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7525852-2300816,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7525852-2370865,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7525852-2459713,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7525852-2501444,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7525852-2788225,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7525852-301171,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7525852-306413,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7525852-6230784,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7525852-6260988,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7525852-8093892,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7525852-8163931,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7525852-8386743,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7525852-8387458,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7525852-8394220,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7525852-8397273,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7525852-8491198
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0022-1007
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
180
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2347-51
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:7525852-Animals,
pubmed-meshheading:7525852-B-Lymphocytes,
pubmed-meshheading:7525852-CD4-Positive T-Lymphocytes,
pubmed-meshheading:7525852-DNA, Viral,
pubmed-meshheading:7525852-Kinetics,
pubmed-meshheading:7525852-Lymph Nodes,
pubmed-meshheading:7525852-Mammary Tumor Virus, Mouse,
pubmed-meshheading:7525852-Mice,
pubmed-meshheading:7525852-Mice, Inbred BALB C,
pubmed-meshheading:7525852-Mice, Inbred Strains,
pubmed-meshheading:7525852-Phenotype,
pubmed-meshheading:7525852-Polymerase Chain Reaction,
pubmed-meshheading:7525852-RNA-Directed DNA Polymerase,
pubmed-meshheading:7525852-Superantigens,
pubmed-meshheading:7525852-T-Lymphocytes,
pubmed-meshheading:7525852-Virus Replication,
pubmed-meshheading:7525852-Zidovudine
|
|
pubmed:year |
1994
|
|
pubmed:articleTitle |
Reverse transcriptase-dependent and -independent phases of infection with mouse mammary tumor virus: implications for superantigen function.
|
|
pubmed:affiliation |
Ludwig Institute for Cancer Research, University of Lausanne, Epalinges, Switzerland.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|
